Knight Reports First Quarter 2014 Results
MONTREAL, QUEBEC–(Marketwired – May 28, 2014) – Knight Therapeutics Inc. (“Knight”) (TSX:GUD) today reported its financial results for the quarter ended March 31, 2014. 1st Quarter 2014 Highlights Listed on TSX-V on February 28, 2014 and began trading on TSX-V under the ticker symbol GUD.V on March 3, 2014. Entered into and completed a private […]
Knight Therapeutics Engages Genesys Capital Management to Assist with Business Development
MONTREAL, CANADA–(Marketwired – May 1, 2014) – Knight Therapeutics Inc. (“Knight”) (TSX:GUD) announced today that Genesys Capital Management Inc. (“Genesys”) has been engaged to assist Knight with its business development efforts. The mandate includes lending money on a secured basis to emerging biotechnology and specialty pharmaceutical companies in order to gain access to innovative products […]
Knight Therapeutics Inc. Commences Trading on TSX
MONTREAL, QUEBEC–(Marketwired – April 29, 2014) – Knight Therapeutics Inc. (“Knight”) (TSX:GUD) announced that later today its common shares will commence trading on Toronto Stock Exchange. At this same time, its common shares will be de-listed from TSX Venture Exchange. Jonathan Ross Goodman, Chief Executive Officer of Knight and Founder of both Paladin Labs Inc. […]
Knight Therapeutics Announces Receipts for Final Prospectuses and Conditional Approval for Listing on the Toronto Stock Exchange
MONTREAL, CANADA–(Marketwired – April 17, 2014) – THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Knight Therapeutics Inc. (“Knight” or the “Company”) (TSX VENTURE:GUD) today announced that it has received receipts dated April 17, 2014 for […]
Knight Therapeutics Completes Previously Announced “Bought Deal” Private Placement of Special Warrants for Gross Proceeds of Approximately $180 Million
MONTREAL, CANADA–(Marketwired – April 10, 2014) – THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Knight Therapeutics Inc. (“Knight” or the “Company”) (TSX VENTURE:GUD) today announced that it has completed its previously announced offering through a […]
Knight Therapeutics Enters into Agreement for a $75 Million “Bought Deal” Private Placement of Special Warrants
MONTREAL, QUEBEC–(Marketwired – March 21, 2014) – THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Knight Therapeutics Inc. (“Knight” or the “Company”) (TSX VENTURE:GUD) today announced that it has entered into a letter agreement with a […]
Knight Therapeutics Announces Increase of Previously Announced “Bought Deal” Private Placement of Special Warrants to $180 Million
MONTREAL, QUEBEC–(Marketwired – March 21, 2014) – THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Knight Therapeutics Inc. (“Knight” or the “Company”) (TSX VENTURE:GUD) is pleased to announce that it has amended the terms of its […]
Knight Therapeutics Completes Previously Announced “Bought Deal” Private Placement of Special Warrants for Gross Proceeds of Approximately $75 Million
MONTREAL, CANADA–(Marketwired – March 19, 2014) – THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Knight Therapeutics Inc. (“Knight” or the “Company”) (TSX VENTURE:GUD) today announced that it has completed its previously announced offering to a […]
Knight Therapeutics Inc. Announces FDA Approval for Impavido® (Miltefosine) for the Treatment of Visceral, Mucosal and Cutaneous Leishmaniasis
Awarded Priority Review Voucher MONTREAL, QUEBEC–(Marketwired – March 19, 2014) – Knight Therapeutics Inc. (“Knight”) (TSX VENTURE:GUD) today announced that the U.S. Food and Drug Administration (FDA) has approved Impavido® (Miltefosine) for patients with Visceral, Mucosal and Cutaneous Leishmaniasis. Also received today was a Priority Review Voucher, which is designed to be transferable or sold […]
Knight Therapeutics Announces Over-Allotment Option in Previously Announced “Bought Deal” Private Placement of Special Warrants, Bringing Expected Proceeds to $75 Million
p>MONTREAL, QUEBEC–(Marketwired – March 6, 2014) – THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Knight Therapeutics Inc. (“Knight” or the “Company”) (TSX VENTURE:GUD) is pleased to announce that due to the positive market reaction to […]
